Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel/Gemcitabine Induction and Chemo-RT +/- Consolidation in Stage III NSCLC
NCT00431613Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Mar 2006
- Primary completion
- Feb 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Hellenic Oncology Research Group. Primary endpoint: Time to tumor progression at 1 year. Started Mar 2006; status: terminated.
02
Drugs
docetaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00431613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431613.